<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="140429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272830</url>
  </required_header>
  <id_info>
    <org_study_id>Summa-09136</org_study_id>
    <nct_id>NCT01272830</nct_id>
  </id_info>
  <brief_title>Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements</brief_title>
  <acronym>Apatone-B</acronym>
  <official_title>A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IC-MedTech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Summa Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crystal Clinic Orthopaedic Center LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IC-MedTech Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being conducted to determine if taking oral (by mouth in pill form)
      Apatone®B (a combination of Vitamins C and K3) will reduce chronic joint discomfort and
      improve function of non-infected symptomatic postoperative total joint replacements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To perform a prospective, randomized, double-blind clinical trial to determine if oral
      Apatone®B, an amalgam of vitamins C and K3, has a therapeutic efficacy beyond the
      conservative care customarily used to reduce inflammatory synovitis and to increase the
      functional capacity of proven non-infected symptomatic postoperative total joint
      replacements.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surrogate Endpoint Biomarkers</measure>
    <time_frame>13-weeks</time_frame>
    <description>Biochemical, Functional, and Emotional endpoints</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Edematous</condition>
  <condition>Synovitis</condition>
  <condition>Foreign Body Reaction</condition>
  <condition>Osteolysis</condition>
  <arm_group>
    <arm_group_label>oral Apatone®B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An amalgum of Vitamins C &amp; K3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsule of similar appearance and taste without Apatone®B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two capsules taken twice daily with meals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatone®B</intervention_name>
    <description>Two capsules taken twice daily with meals</description>
    <arm_group_label>oral Apatone®B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postoperative Total joint replacement with osteoarthritis as the underlying pathology

          -  Proven non-infected symptomatic TJA (joint implanted for &gt;12 months post-op)

          -  Age (50 to 85 years of age); based on a 10% trim of the age distribution for Summa
             Health System TJAs (7/1/08-6/30/2009).

        Exclusion Criteria:

          -  An infection of any kind (prior to, or during the study)

          -  Rheumatoid arthritis as the underlying pathology

          -  Cortisone injection received &lt;6 months prior to study enrollment

          -  Insulin dependent diabetes

          -  Diagnosed immunodeficiency

          -  On dialysis or have poor kidney function

          -  Anti-coagulant medication (e.g., Coumadin or &gt;100mg of Aspirin daily)

          -  Anti-seizure medication (e.g., Dilantin)

          -  Steroidal medication (e.g., Prednisone, Advair or Symbicort)

          -  NSAIDS (e.g., Celebrex or Toadol); a 14-day washout period will be allowed

          -  bisphosphonates (e.g., Fosamax, Actonel, Aredia, Didronel, Boniva or Reclast)

          -  hormonal therapy (e.g., Estrogen, Progesterone or Testosterone)

          -  Cancer (active or in remission)

          -  Planned concurrent vitamins exceeding a standard daily multivitamin or exceeding the
             RDA for individual vitamins if used alone; a 72 hour wash out period will be allowed

          -  A glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Pregnant or lactating; females who are in their reproductive years must have a
             negative serum pregnancy

          -  Lactose intolerant

          -  Citric acid intolerant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F Bear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Crystal Clinic Orthopaedic Center LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark W Kovacik, BS</last_name>
    <role>Study Director</role>
    <affiliation>Summa Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Summa Health System</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 25, 2015</lastchanged_date>
  <firstreceived_date>December 17, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total joint arthroplasty</keyword>
  <keyword>synovitis</keyword>
  <keyword>ALVAL</keyword>
  <keyword>osteolysis</keyword>
  <keyword>periprosthetic metallosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Synovitis</mesh_term>
    <mesh_term>Osteolysis</mesh_term>
    <mesh_term>Foreign Bodies</mesh_term>
    <mesh_term>Foreign-Body Reaction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
